Key facts
- It has raised $29.5M; the latest was Later Stage VC ($14.0M) in Nov 2025.
- Notable investors include Baidu Ventures, Chengdu Bio-Town Investment, Qingdao Haier Venture Capital, Beihang Investment, Beijing LF Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ECHO Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for ECHO Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ECHO Biotech
Developer of scientific research services and drugs intended for exosomes technology and treatment. The company focuses on the research and clinical transformation exosome technology and combines more than ten years of basic exosome research with molecular biology, cell biology and bioinformatics technology, and has established a leading exosome research and transformation platform, providing exosomes-based scientific and technological services and innovative drugs based on exosomes as carriers, which mainly cover the fields of tumor immunity, neurology and rare diseases.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 29
- Website
- echobiotech.com/index.php
- Ownership
- Privately Held (backing)
ECHO Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ECHO Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ECHO Biotech in its N-PORT filings yet. We sweep new filings monthly.